查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1735632

全球白喉-破伤风-百日咳疫苗市场规模（依产品类型、年龄层、最终用户、区域范围和预测）

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Size By Product Type, By Age Group, By End-User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

白喉、破伤风、百日咳联合疫苗市场规模的变迁及预测

2024 年白喉、破伤风和百日咳疫苗市场规模价值 5,500,460 亿美元，预计到 2032 年将达到 8,232,550 亿美元，2026 年至 2032 年的复合年增长率为 5.17%。

  • DTaP 疫苗是一种联合疫苗，含有灭活的白喉梭菌和破伤风梭菌毒素或成分以及百日咳博德氏菌抗原。它通常作为常规儿童免疫接种的一部分，用于婴幼儿。此疫苗可刺激人体免疫系统产生针对这些细菌病原体的抗体，从而提供免疫力并预防这些病原体引起的疾病。
  • 白喉是一种细菌感染疾病，可引起严重的呼吸道症状和危及生命的併发症。 DTaP 疫苗透过刺激免疫系统产生抗体来中和白喉细菌产生的毒素，从而预防白喉。
  • 破伤风是一种细菌感染疾病，会影响神经系统，并导致肌肉僵硬和痉挛。 DTaP疫苗含有一种成分，可诱发身体对破伤风桿菌所产生的毒素产生免疫力。
  • 百日咳是一种以剧烈咳嗽为特征的传染性呼吸道感染疾病。 DTaP 疫苗含有百日咳博德氏菌抗原，可刺激人体产生抗体，进而预防百日咳感染。
  • 正在进行的研究旨在开发 DTaP 疫苗的改良配方，以提高效力、安全性和保护时间，包括开发新的佐剂、递送系统和抗原组合，以优化免疫反应并减少副作用。

白喉-破伤风-百日咳疫苗市场动态

影响全球白喉破伤风百日咳疫苗市场的关键市场动态：

关键市场驱动因素

  • 疫苗接种意识不断增强：父母、看护者和医疗保健专业人员越来越意识到接种疫苗在预防白喉、破伤风和百日咳等疾病方面的重要性，在教育宣传活动和公共卫生倡议的推动下，对 DTaP 疫苗的需求激增，从而扩大了市场。
  • 百日咳发病率上升：百日咳疫情的爆发源自于复杂的疾病传播机制和群体免疫的挑战。促成因素包括免疫力下降、疫苗接种覆盖率不全、百日咳桿菌的演化。诊断困难导致治疗延误，并增加感染风险。百日咳患者数量的增加将推动市场成长。
  • 医疗保健支出不断增长：新兴经济体医疗保健支出的不断增长，正在鼓励对预防措施（尤其是疫苗接种计划）的投资。医疗保健机构透过与政府机构和国际组织的合作，广泛确保疫苗接种和分发，尤其是在医疗资源匮乏和偏远地区。对预防性健康措施（尤其是疫苗接种计划）日益增长的投入，正在推动市场成长。
  • 疫苗製剂的进步：创新的製剂策略、佐剂、呈现抗原系统和增强的递送机制提高了 DTaP 疫苗的性能，提高了其稳定性、保质期和易用性，从而促进了其市场扩张。

主要挑战

  • 疫苗供不应求：生产中断，例如设备故障和品管问题，可能会阻碍DTaP疫苗的生产，并导致供应不足。供应链中断，例如运输延误和储存问题，可能会加剧供不应求，阻碍疫苗及时分发至医疗保健和疫苗接种点，并扰乱联合疫苗的生产和交付。
  • 低温运输管理挑战：低温运输管理对疫苗的有效性至关重要，但温度波动可能会影响其有效性。电力、冷冻和交通基础设施匮乏的偏远地区在低温运输管理方面面临更多挑战。缺乏适当的处理通讯协定进一步限制了白喉-破伤风-百日咳疫苗市场的发展。
  • 成本问题：由于资源限制、供应有限、物流障碍和定价问题，白喉-破伤风-急性百日咳疫苗在低收入和中等收入国家难以取得。这可能会阻碍疫苗接种，并扩大免疫覆盖缺口。医疗机构难以维持稳定的库存，导致错失为儿童（尤其是弱势儿童）接种疫苗的机会。配送物流，尤其是在偏远和服务不足的地区，可能会阻碍联合疫苗市场的成长。

主要趋势

  • 疫苗配方改进：DTaP 疫苗正在持续研究，以改善配方、安全性和保护持续时间。这包括研究新型佐剂、递送机制和抗原组合，以优化免疫反应并最大程度地减少副作用，从而为市场成长创造机会。
  • 研究与发展：研究正在推进DTaP疫苗技术，以提高其有效性、安全性和可近性。 mRNA疫苗技术就是这样一种技术，它利用合成的mRNA分子产生特异性抗原，引发强烈的免疫反应。这种方法具有快速开发、扩充性和免疫抗原性等优势。此外，类病毒颗粒、脂质体和奈米颗粒载体等新型抗原递送平台也正在研究中。
  • 联合疫苗：人们对开发联合疫苗（例如 DTaP 疫苗）的兴趣日益浓厚，因为它们可能能够透过单一配方提供对更广泛感染疾病的保护。

目录

第一章全球DTaP联合疫苗市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球DTaP联合疫苗市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球 DTaP 联合疫苗市场（依产品类型）

  • 概述
  • DTaP
  • TD
  • Tdap

6. 全球DTaP联合疫苗市场（依年龄层）

  • 概述
  • 成人
  • 孩子们

7. 全球DTaP联合疫苗市场（按最终用户）

  • 概述
  • 医院
  • 诊所
  • 疫苗接种中心

8. 全球DTaP联合疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

9.全球DTaP联合疫苗市场竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • Bionet-Asia
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Mass biologics
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Panacea Biotech Ltd.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • namely AJ Vaccines

第十一章 公司简介 附录

  • 相关调查
简介目录
Product Code: 35919

Diphtheria, Tetanus And Acellular Pertussis Combined Vaccine Market Size And Forecast

Diphtheria, Tetanus And Acellular Pertussis Combined Vaccine Market size was valued at USD 5500.46 Million in 2024 and is projected to reach USD 8232.55 Million by 2032, growing at a CAGR of 5.17% from 2026 to 2032.

  • The DTaP vaccine is a combination vaccine that contains inactivated toxins or components of the diphtheria and tetanus bacteria, as well as antigens from the Bordetella pertussis bacterium. It is administered through a series of shots typically given to infants and young children as part of routine childhood immunization schedules. The vaccine stimulates the body's immune system to produce antibodies against these bacterial pathogens, providing immunity and protection against the diseases they cause.
  • Diphtheria is a bacterial infection that can cause severe respiratory symptoms and potentially life-threatening complications. The DTaP vaccine helps prevent diphtheria by stimulating the immune system to produce antibodies that neutralize the toxins produced by the bacterium Corynebacterium diphtheriae.
  • Tetanus is a bacterial infection that affects the nervous system, leading to muscle stiffness and spasms. The DTaP vaccine includes a component that induces immunity against the toxin produced by the bacterium Clostridium tetani, which causes tetanus.
  • Pertussis is a highly contagious respiratory infection characterized by severe coughing fits. The DTaP vaccine contains antigens from Bordetella pertussis, which stimulate the production of antibodies to protect against pertussis infection.
  • Ongoing research aims to develop improved formulations of the DTaP vaccine with enhanced efficacy, safety, and duration of protection. This includes the development of newer adjuvants, delivery systems, and antigen combinations to optimize immune responses and reduce side effects.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Dynamics

The key market dynamics that are shaping the global diphtheria, tetanus, and acellular pertussis combined vaccine market include:

Key Market Drivers:

  • Growing Awareness about Vaccination: The growing awareness of the importance of vaccination in preventing diseases like diphtheria, tetanus, and pertussis among parents, caregivers, and healthcare practitioners has led to a surge in demand for DTaP vaccines, fueled by educational campaigns and public health initiatives, resulting in market expansion.
  • Increasing Incidence of Pertussis: Pertussis outbreaks are a result of complex disease transmission and challenges in achieving herd immunity. Factors include waning immunity, incomplete vaccination coverage, and the evolution of Bordetella pertussis. Diagnosis is difficult, leading to treatment delays and increased risk of transmission. Rising cases of pertussis enable market growth.
  • Growing Healthcare Expenditure: The rise in healthcare expenditure in developing economies is driving investments in preventive measures, particularly vaccination programs. Healthcare providers, through partnerships with government agencies and international organizations, ensure widespread vaccine access and distribution, especially in underserved and remote areas. This growing commitment to preventive healthcare measures, particularly vaccination programs, is boosting market growth.
  • Growing advancements in vaccine formulations: Research is enhancing DTaP vaccine performance through innovative formulation strategies, enhancing adjuvants, antigen presentation systems, and delivery mechanisms, leading to improved stability, shelf-life, and administration ease, thereby promoting market expansion.

Key Challenges:

  • Vaccine Supply Shortages: Manufacturing disruptions, such as equipment malfunctions or quality control issues, can impede the production of DTaP vaccines, leading to inadequate supply levels. Supply chain disruptions, like transportation delays or storage issues, can exacerbate shortages and hinder timely distribution to healthcare facilities and vaccination sites, thereby challenging the manufacturing and supply of the combined vaccine.
  • Cold Chain Management Challenges: Cold chain management is crucial for vaccine efficacy, but temperature fluctuations can compromise effectiveness. Remote areas with limited access to electricity, refrigeration, and transportation infrastructure face additional challenges in cold chain management. Lack of proper handling protocols further restricts the combined diphtheria, tetanus, and acellular pertussis vaccine market.
  • Concerns Regarding Costing: DTaP vaccines are challenging to access in low- and middle-income countries due to resource constraints, limited availability, logistical hurdles, and affordability issues. This can impede vaccination efforts and increase immunization coverage disparities. Healthcare facilities struggle to maintain consistent stocks, leading to missed vaccination opportunities, especially for vulnerable children. Distribution logistics, particularly in remote or underserved areas, may hinder the combined vaccine market growth.

Key Trends:

  • Improved Vaccine Formulations: The DTaP vaccine is under continuous research to improve its formulations, safety, and protection duration. This involves exploring novel adjuvants, delivery mechanisms, and antigen combinations to optimize immune responses and minimize side effects, creating market growth opportunities.
  • Research and Development: Research is advancing DTaP vaccine technology to improve efficacy, safety, and accessibility. One innovation is mRNA vaccine technology, which uses synthetic mRNA molecules to produce specific antigens, triggering robust immune responses. This approach offers rapid development, scalability, and enhanced immunogenicity. Novel antigen delivery platforms like virus-like particles, liposomes, and nanoparticle carriers are also being explored.
  • Combination Vaccines: The development of combination vaccines, such as the DTaP vaccine, is gaining interest due to its potential to offer protection against a wider range of infectious diseases in a single formulation.

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global diphtheria, tetanus, and acellular pertussis combined vaccine market:

North America:

  • North America is poised to maintain a substantial stake in the DTaP combined vaccine market, propelled by its robust healthcare infrastructure, elevated vaccination rates, and comprehensive government-driven immunization campaigns.
  • The region benefits from cutting-edge technological advancements, fortified by stringent regulatory frameworks, which collectively bolster the market's growth trajectory.
  • Moreover, heightened disease awareness among both healthcare professionals and the general populace further amplifies the demand for DTaP vaccines in North America.
  • This comprehensive ecosystem fosters a conducive environment for the continued expansion of the DTaP Combined Vaccine Market, ensuring widespread accessibility and efficacy of preventive healthcare measures against diphtheria, tetanus, and pertussis throughout the region.

Europe:

  • Europe stands out as a significant market for DTaP vaccines, distinguished by its well-established vaccination policies, comprehensive immunization coverage, and proactive approaches to disease prevention.
  • Europe's commitment to research and development (R&D) fosters innovation in vaccine technology and formulation. Increasing investments in R&D initiatives, alongside collaborations between public health agencies, academic institutions, and vaccine manufacturers, drive advancements in DTaP vaccine development.
  • Europe's proactive disease prevention strategies focus on early detection, surveillance, and response to infectious diseases, including those preventable by vaccination.
  • Strong partnerships between public health authorities and healthcare providers enhance disease surveillance efforts, enabling timely interventions to control disease outbreaks and minimize their impact on public health.

Asia Pacific:

  • Rapid urbanization and population growth in countries like China, India, and Japan further contribute to the expansion of the DTaP Combined Vaccine Market. As urban populations increase, so does the demand for healthcare services, including immunization.
  • Governments in these countries are implementing initiatives to strengthen healthcare infrastructure and improve access to healthcare services in both urban and rural areas, thereby facilitating the expansion of immunization programs.
  • Additionally, government initiatives aimed at enhancing healthcare infrastructure play a crucial role in driving market expansion.
  • Investments in healthcare facilities, vaccination clinics, and cold chain logistics contribute to the efficient delivery and distribution of DTaP vaccines, ensuring that they reach remote and underserved areas.

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market: Segmentation Analysis

The Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market is segmented based on Product Type, Age Group, End User, And Geography.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Product Type

  • DTaP Vaccines
  • TD Vaccines
  • Tdap Vaccines

Based on Product Type, the market is categorized into DTaP, TD, and Tdap. The DTaP segment dominated the global DTP vaccine market. The demand for DTaP and pertussis vaccines is driving global growth. WHO states immunization can prevent 3.5-5 million deaths annually. Since vaccines were introduced, few respiratory diphtheria cases have been reported by the CDC. Unvaccinated travelers face high infection risks, so governments mandate immunization for travelers visiting countries with infectious diseases. According to WHO In 2022, Coverage of a third dose of a vaccine protecting against diphtheria, tetanus, and pertussis (DTP3) recovered from 81% in 2021 to 84% in 2022. High birth rates, government initiatives, and insurance drive the DTaP vaccine market growth.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Age Group

  • Adult Vaccines
  • Pediatric Vaccines

Based on Age Group, the DTP vaccines market is segmented into Pediatric Vaccines and Adult Vaccines. By age group, the market for vaccines for adults is expected to experience significant growth due to the increase in infectious diseases among adults. Moreover, the segment is likely to see an upsurge in growth due to advancements in research and development and a strong product pipeline during the forecast period. However, the pediatric segment currently dominates the market due to the high demand for DTP vaccines among infants. The pediatrics vaccines segment's potential size is based on the fact that the global birth rate is increasing, boosting the demand for pediatric vaccines.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By End-User

  • Hospitals
  • Clinics
  • Vaccination Centre

Based on End-User, the market is fragmented into Hospitals, Clinics, and Vaccination Centre. The hospital segment dominated the largest market share throughout the forecast period. Hospitals play a pivotal role as primary healthcare providers, offering a wide array of medical services, including immunization. As key end-users of DTaP vaccines, hospitals serve as vital hubs for administering preventive healthcare measures to individuals across all age groups, from newborns to adults. Their significance lies in their ability to provide comprehensive vaccination services, encompassing routine immunizations as well as rapid responses to disease outbreaks.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Diphtheria, Tetanus, And Acellular Pertussis Combined Vaccine is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share of Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccines. Well-established healthcare infrastructure, high vaccination rates, and robust immunization programs contribute to the dominance of the DTP vaccine market. Moreover, ongoing advancements in medical technology and strong regulatory frameworks further bolster market growth in this region.

Key Players

  • The "Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, namely AJ Vaccines, and GlaxoSmithKline plc. Merck & Co. Inc., Sanofi, Bionet-Asia, Mass biologics, Meiji Holdings Co., Ltd., Panacea Biotech Ltd., and Serum Institute of India Pvt. Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Recent Developments
  • In October 2022, the FDA approved Boostrix for pregnant women in their third trimester to prevent pertussis in infants under 2 months old.
  • In June 2021, Merck and Sanofi's VAXELIS, the first and only six-in-one pediatric combination vaccine, is now available in the U.S. The vaccine is approved for use in children aged 6 weeks to 4 years to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DTaP COMBINED VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL DTaP COMBINED VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL DTaP COMBINED VACCINE MARKET, BY PRODUCT TYPE

  • 5.1 Overview
  • 5.2 DTaP
  • 5.3 TD
  • 5.4 Tdap

6 GLOBAL DTaP COMBINED VACCINE MARKET, BY AGE GROUP

  • 6.1 Overview
  • 6.2 Adult
  • 6.3 Pediatric

7 GLOBAL DTaP COMBINED VACCINE MARKET, BY END USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Clinics
  • 7.4 Vaccination Centers

8 GLOBAL DTaP COMBINED VACCINE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL DTaP COMBINED VACCINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Bionet-Asia
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Johnson & Johnson
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 GlaxoSmithKline plc
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Mass biologics
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Meiji Holdings Co., Ltd.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Merck & Co., Inc.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Panacea Biotech Ltd.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Sanofi
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Serum Institute of India Pvt. Ltd.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 namely AJ Vaccines
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Research